EMD Serono takes on exclusive promotion of Rebif in USA

19 January 2016

EMD Serono, the North American biopharma business of Germany’s Merck KGaA (MRK: DE), has taken on the sole rights to Rebif (interferon beta-1a) in the USA as of January 1.

Rebif, the number one prescribed interferon for relapsing multiple sclerosis (MS) in patients new to therapy in the USA, is now the exclusive interferon beta-1a on CVS Caremark National Formulary and will also continue to be covered on most major national formulary plans.

"We have also evolved our award-winning MS LifeLines patient support service with the goal of providing a broad range of comprehensive assistance to people living with relapsing MS," said Drew Young, senior vice president, neurology and immunology, EMD Serono. "Since reimbursement can often be complicated for patients to navigate, we are working to ensure that all eligible patients are aware of our comprehensive suite of patient support programs, including our reimbursement support," he added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK